ORIC Live signals | Maximize Profits with Getagraph.com

BUY 88488 min ago

@ $11.31

Issued: 14 Feb 2024 @ 14:07

Return: -15.64%

Previous signal: Feb 13 - 13:45

Previous signal: Sell

Return: -1.65 %

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 16:00):

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States...

Stats
Today's Volume	332 113
Average Volume	611 662
Market Cap	642.77M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.440 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.87
ATR14	$0.0130 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Chacko Jacob	Sell	40 000	Common Stock
2024-02-06	Chacko Jacob	Sell	13 958	Common Stock
2024-02-07	Chacko Jacob	Sell	26 042	Common Stock
2024-01-02	Multani Pratik S	Buy	180 000	Stock Option (right to buy)
2024-01-02	Multani Pratik S	Buy	30 000	Restricted Stock Unit

INSIDER POWER
53.52
Last 99 transactions
Buy: 6 373 472 \| Sell: 3 807 004

Volume Correlation

Long: -0.14 (neutral)

Short: -0.81 (strong negative)

Signal:(64.186) Neutral

Oric Pharmaceuticals Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oric Pharmaceuticals Inc Correlation - Currency/Commodity

0.25
( neutral )

0.29
( neutral )

0.00
( neutral )

-0.35
( neutral )

0.32
( neutral )

-0.35
( neutral )

Oric Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.03M (0.00 %)
EPS:	$-1.960

Q4	2023
Revenue:	$0
Gross Profit:	$-263 000 (0.00 %)
EPS:	$-0.490

Q3	2023
Revenue:	$0
Gross Profit:	$-257 000 (0.00 %)
EPS:	$-0.440

Q2	2023
Revenue:	$0
Gross Profit:	$-259 000 (0.00 %)
EPS:	$-0.500

Financial Reports:

No articles found.

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.